PanGenetics raises €13M in second round
PanGenetics BV has raised 13 million euros in its second round of venture capital. The funds will enable PanGenetics to continue clinical development of its human CD40 antagonist, PG102, with a view to filing an IND in the first quarter of 2007.
- here's the release for more information
Comments